DexCom, Inc. provides revenue guidance for the fourth quarter and full year ended December 31, 2020 and fiscal year 2021. For the quarter, the company expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2020 to meet or exceed $567 million, an increase of 23% over the fourth quarter of 2019. For the fiscal 2020, the company expects total preliminary, unaudited revenue to meet or exceed $1.925 billion, an increase of more than 30% over 2019. For the year 2021, the company anticipates total revenue to be approximately $2.21 billion to $2.31 billion, representing expected growth of approximately 15% to 20% over 2020. This growth outlook considers sensor volume growth driven by increasing CGM awareness for people with Type 1 and Type 2 diabetes, continued international expansion, shifting channel mix and overall market dynamics.